Question to the Home Office:

To ask the Secretary of State for the Home Department, what assessment her Department has made of the potential impact of the reclassification of ketamine as a class B drug on the rate of usage among 16 to 24 year olds annually since 2015.

Answered by Sarah Jones - Minister of State (Home Office)

Ketamine is a dangerous substance, which can cause irreversible bladder damage and in some cases death. Ministers are very concerned about the harms ketamine causes and on 16 October 2025 the Department for Health and Social Care launched a campaign to alert young people to the dangers of that drug (as well as counterfeit medicines containing synthetic opioids, and THC vapes).

Ketamine was moved from Class C to Class B within Schedule 2 to the Misuse of Drugs Act 1971 (MDA) in 2014, following a review of its harms by the Advisory Council on the Misuse of Drugs (ACMD). The ACMD noted that “although there is limited evidence of ketamine misuse causing social harm, evidence of physical harm (mainly chronic bladder toxicity but also an increase in acute toxicity) has increased”.

We have not carried out an assessment of the effects of that reclassification. The drivers of the availability, market price and prevalence of drugs are complex. The control of drugs under the MDA is an important means of reducing their availability and gives law enforcement the powers to target criminals involved in supplying harmful substances. In 2024 there were 2,014 prosecutions and 1,507 convictions in England and Wales for offences relating to the possession and trafficking of ketamine.

In January 2025 the Government asked the ACMD to provide an updated harms assessment of ketamine. The ACMD carried out a public call for evidence in August and we expect to receive its report by the end of 2025. We will carefully consider its recommendations.

Question to the Home Office:

To ask the Secretary of State for the Home Department, what assessment her Department has made of the potential impact of the reclassification of ketamine as a class B drug on the rate of usage among 16 to 59 year olds annually since 2015.

Answered by Sarah Jones - Minister of State (Home Office)

Ketamine is a dangerous substance, which can cause irreversible bladder damage and in some cases death. Ministers are very concerned about the harms ketamine causes and on 16 October 2025 the Department for Health and Social Care launched a campaign to alert young people to the dangers of that drug (as well as counterfeit medicines containing synthetic opioids, and THC vapes).

Ketamine was moved from Class C to Class B within Schedule 2 to the Misuse of Drugs Act 1971 (MDA) in 2014, following a review of its harms by the Advisory Council on the Misuse of Drugs (ACMD). The ACMD noted that “although there is limited evidence of ketamine misuse causing social harm, evidence of physical harm (mainly chronic bladder toxicity but also an increase in acute toxicity) has increased”.

We have not carried out an assessment of the effects of that reclassification. The drivers of the availability, market price and prevalence of drugs are complex. The control of drugs under the MDA is an important means of reducing their availability and gives law enforcement the powers to target criminals involved in supplying harmful substances. In 2024 there were 2,014 prosecutions and 1,507 convictions in England and Wales for offences relating to the possession and trafficking of ketamine.

In January 2025 the Government asked the ACMD to provide an updated harms assessment of ketamine. The ACMD carried out a public call for evidence in August and we expect to receive its report by the end of 2025. We will carefully consider its recommendations.

Question to the Home Office:

To ask the Secretary of State for the Home Department, what assessment her Department has made of the potential impact of the reclassification of ketamine as a class B drug on the average street price of ketamine annually since 2015.

Answered by Sarah Jones - Minister of State (Home Office)

Ketamine is a dangerous substance, which can cause irreversible bladder damage and in some cases death. Ministers are very concerned about the harms ketamine causes and on 16 October 2025 the Department for Health and Social Care launched a campaign to alert young people to the dangers of that drug (as well as counterfeit medicines containing synthetic opioids, and THC vapes).

Ketamine was moved from Class C to Class B within Schedule 2 to the Misuse of Drugs Act 1971 (MDA) in 2014, following a review of its harms by the Advisory Council on the Misuse of Drugs (ACMD). The ACMD noted that “although there is limited evidence of ketamine misuse causing social harm, evidence of physical harm (mainly chronic bladder toxicity but also an increase in acute toxicity) has increased”.

We have not carried out an assessment of the effects of that reclassification. The drivers of the availability, market price and prevalence of drugs are complex. The control of drugs under the MDA is an important means of reducing their availability and gives law enforcement the powers to target criminals involved in supplying harmful substances. In 2024 there were 2,014 prosecutions and 1,507 convictions in England and Wales for offences relating to the possession and trafficking of ketamine.

In January 2025 the Government asked the ACMD to provide an updated harms assessment of ketamine. The ACMD carried out a public call for evidence in August and we expect to receive its report by the end of 2025. We will carefully consider its recommendations.

Question to the Home Office:

To ask the Secretary of State for the Home Department, what assessment her Department has made of the potential impact of the reclassification of ketamine as a class B drug on its illicit availability.

Answered by Sarah Jones - Minister of State (Home Office)

Ketamine is a dangerous substance, which can cause irreversible bladder damage and in some cases death. Ministers are very concerned about the harms ketamine causes and on 16 October 2025 the Department for Health and Social Care launched a campaign to alert young people to the dangers of that drug (as well as counterfeit medicines containing synthetic opioids, and THC vapes).

Ketamine was moved from Class C to Class B within Schedule 2 to the Misuse of Drugs Act 1971 (MDA) in 2014, following a review of its harms by the Advisory Council on the Misuse of Drugs (ACMD). The ACMD noted that “although there is limited evidence of ketamine misuse causing social harm, evidence of physical harm (mainly chronic bladder toxicity but also an increase in acute toxicity) has increased”.

We have not carried out an assessment of the effects of that reclassification. The drivers of the availability, market price and prevalence of drugs are complex. The control of drugs under the MDA is an important means of reducing their availability and gives law enforcement the powers to target criminals involved in supplying harmful substances. In 2024 there were 2,014 prosecutions and 1,507 convictions in England and Wales for offences relating to the possession and trafficking of ketamine.

In January 2025 the Government asked the ACMD to provide an updated harms assessment of ketamine. The ACMD carried out a public call for evidence in August and we expect to receive its report by the end of 2025. We will carefully consider its recommendations.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of cervical cancer self-sampling on reaching under-screened populations; and what targets he has for the uptake of (a) in-clinic and (b) at-home self-sampling options.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

Both the impact assessment and the equality impact assessment on the introduction of human papillomavirus (HPV) self-sampling for the under-screened population in the National Health Service Cervical Screening Programme have been published and is available at the following link:

https://www.gov.uk/government/publications/cervical-screening-hpv-self-sampling-impact-assessments

The UK National Screening Committee’s recommendation for the use of HPV self-sampling was permissive, meaning the NHS can, but does not have to, implement it. They should use it where they believe it can have a useful impact on supporting uptake. There are therefore no national targets at this time.

Drug deaths (No. 2)

Found: Labour, Stafford) Gordon McKee MP (Labour, Glasgow South) Ms Theresa Middleton CBE (Lay Member) Charlotte Nichols